Gershtein E S, Levkina N V, Digayeva M A, Laktionov K P, Tereshkina I V, Kushlinsky N E
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia.
Bull Exp Biol Med. 2010 Oct;149(5):628-31. doi: 10.1007/s10517-010-1010-4.
The content of matrix metalloproteinases 7 and 9 was significantly increased, while the content of metalloproteinase 2 was reduced in ovarian cancer tissue compared to benign tumors. In blood serum from patients with ovarian cancer, the concentrations of matrix metalloproteinases 7 and 9 and their type 1 tissue inhibitor were significantly elevated, while the concentration of matrix metalloproteinase 2 was reduced compared to the corresponding parameters in healthy women. After chemotherapy, tissue and serum concentrations of metalloproteinases and their inhibitor in patients practically returned to normal. A significant positive correlation between serum levels of matrix metalloproteinases 7 and 9 and tissue inhibitor of metalloproteinases-1 in patients with ovarian cancer and the size of primary tumor (ultrasound examination) and a positive correlation between these parameters and the concentration of classical ovarian cancer marker CA-125 were demonstrated.
与良性肿瘤相比，卵巢癌组织中基质金属蛋白酶7和9的含量显著增加，而金属蛋白酶2的含量降低。在卵巢癌患者的血清中，基质金属蛋白酶7和9及其1型组织抑制剂的浓度显著升高，而与健康女性的相应参数相比，金属蛋白酶2的浓度降低。化疗后，患者体内金属蛋白酶及其抑制剂的组织和血清浓度实际上恢复正常。卵巢癌患者血清中基质金属蛋白酶7和9水平与金属蛋白酶组织抑制剂-1以及原发肿瘤大小（超声检查）之间存在显著正相关，并且这些参数与经典卵巢癌标志物CA-125的浓度之间也存在正相关。
